黛立新与西比灵预防性治疗偏头痛疗效比较

Efficacy comparison between deanxit and cinnarizine in preventive treatment of migraine

目的比较黛立新与西比灵预防性治疗偏头痛的疗效。方法选择头痛影响测定-6评分大于60分的偏头痛患者92例,随机分为黛立新组和西比灵组。黛立新组予以黛立新早餐后服用,每天1片;西比灵组予西比灵每晚9时服用,每天10 mg。治疗5周,以问卷"头痛影响测定-6(HIT-6)"于治疗后再次对患者进行评分。结果两组治疗后的HIT-6评分差异有高度统计学意义(P<0.01),黛力新组HIT-6评分减少更明显。结论对头痛影响测定-6评分大于60分的患者,黛立新预防性治疗偏头痛的疗效优于西比灵。

Objective To compare the efficacy between deanxit and cinnarizine in preventive treatment of migraine. Methods All of 92 migraine cases with headache impact Test-6 （HIT-6） scores over 60 were randomly divided into two groups, deanxit and cinnarizine. The deanxit group took deanxit after breakfast, one tablet per day; The cinnarizine group took cinnarizine capsule 9pm every night, 10mg per day. All of the patients after five weeks treatment were scored again with HIT-6 questionaire. Results The HIT-6 score difference of the two groups after treatment was statistic significant （P 〈0.01）, and the scores of the deanxit group decreased more. Conclusion The efficacy of deanxit in preventive treatment of migraine is better than that of cinnarizine for patients whose HIT-6 score is over 60.